{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:55:54Z","timestamp":1793148954041,"version":"4.5.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,22]],"date-time":"2022-04-22T00:00:00Z","timestamp":1650585600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002873","name":"Chulalongkorn University","doi-asserted-by":"publisher","award":["417\/63"],"award-info":[{"award-number":["417\/63"]}],"id":[{"id":"10.13039\/501100002873","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007693","name":"King Chulalongkorn Memorial Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007693","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.ijid.2022.04.052","type":"journal-article","created":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T01:50:34Z","timestamp":1651024234000},"page":"96-102","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["Therapeutic drug monitoring of meropenem and pharmacokinetic-pharmacodynamic target assessment in critically ill pediatric patients from a prospective observational study"],"prefix":"10.1016","volume":"120","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7463-7715","authenticated-orcid":false,"given":"Passara","family":"Maimongkol","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6658-0082","authenticated-orcid":false,"given":"Wanlika","family":"Yonwises","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6965-5537","authenticated-orcid":false,"given":"Suvaporn","family":"Anugulruengkitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiratchaya","family":"Sophonphan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5274-1922","authenticated-orcid":false,"given":"Wanchai","family":"Treyaprasert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1499-6940","authenticated-orcid":false,"given":"Noppadol","family":"Wacharachaisurapol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2022.04.052_bib0001","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00134-020-06050-1","article-title":"Antimicrobial therapeutic drug monitoring in critically ill adult patients: a position paper","volume":"46","author":"Abdul-Aziz","year":"2020","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.ijid.2022.04.052_bib0002","doi-asserted-by":"crossref","first-page":"e388","DOI":"10.1097\/PCC.0000000000001228","article-title":"Augmented renal clearance using population-based pharmacokinetic modeling in critically ill pediatric patients","volume":"18","author":"Avedissian","year":"2017","journal-title":"Pediatr Crit Care Med"},{"key":"10.1016\/j.ijid.2022.04.052_bib0003","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3389\/fmed.2019.00074","article-title":"Treatment of infections due to MDR Gram-negative bacteria","volume":"6","author":"Bassetti","year":"2019","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.ijid.2022.04.052_bib0004","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.addr.2014.07.006","article-title":"The effect of pathophysiology on pharmacokinetics in the critically ill patient\u2014concepts appraised by the example of antimicrobial agents","volume":"77","author":"Blot","year":"2014","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.ijid.2022.04.052_bib0005","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jchromb.2012.09.016","article-title":"A method for determining the free (unbound) concentration of ten beta-lactam antibiotics in human plasma using high performance liquid chromatography with ultraviolet detection","volume":"907","author":"Briscoe","year":"2012","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1016\/j.ijid.2022.04.052_bib0006","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ijid.2021.05.044","article-title":"Comparison of piperacillin plasma concentrations in a prospective randomised trial of extended infusion versus intermittent bolus of piperacillin\/tazobactam in paediatric patients","volume":"108","author":"Chongcharoenyanon","year":"2021","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.ijid.2022.04.052_bib0007","first-page":"276","article-title":"Population pharmacokinetics and pharmacodynamic target attainment of meropenem in critically ill young children","volume":"22","author":"Cies","year":"2017","journal-title":"J Pediatr Pharmacol Ther"},{"key":"10.1016\/j.ijid.2022.04.052_bib0008","series-title":"Performance standards for antimicrobial susceptibility testing","year":"2021"},{"key":"10.1016\/j.ijid.2022.04.052_bib0009","doi-asserted-by":"crossref","first-page":"5535","DOI":"10.1128\/AAC.00787-15","article-title":"Pharmacokinetics and pharmacodynamics of continuous-infusion meropenem in pediatric hematopoietic stem cell transplant patients","volume":"59","author":"Cojutti","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2022.04.052_bib0010","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1007\/s00134-013-3187-2","article-title":"Therapeutic drug monitoring-based dose optimisation of piperacillin and meropenem: a randomised controlled trial","volume":"40","author":"De Waele","year":"2014","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.ijid.2022.04.052_bib0011","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s15010-016-0885-z","article-title":"Strategies to enhance rational use of antibiotics in hospital: a guideline by the German Society for Infectious Diseases","volume":"44","author":"de With","year":"2016","journal-title":"Infection"},{"key":"10.1016\/j.ijid.2022.04.052_bib0012","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00467-018-4120-2","article-title":"Augmented renal clearance in pediatric intensive care: are we undertreating our sickest patients?","volume":"35","author":"Dhont","year":"2020","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.ijid.2022.04.052_bib0013","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1093\/cid\/cis856","article-title":"Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial","volume":"56","author":"Dulhunty","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2022.04.052_bib0014","doi-asserted-by":"crossref","first-page":"R206","DOI":"10.1186\/cc10441","article-title":"Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of \u03b2-lactams","volume":"15","author":"Gon\u00e7alves-Pereira","year":"2011","journal-title":"Crit Care"},{"key":"10.1016\/j.ijid.2022.04.052_bib0015","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1093\/cid\/ciu069","article-title":"Treatment of multidrug-resistant Gram-negative infections in children","volume":"58","author":"Hsu","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2022.04.052_bib0016","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.ijantimicag.2011.04.019","article-title":"Pharmacodynamics of meropenem in critically ill patients with febrile neutropenia and bacteraemia","volume":"38","author":"Jaruratanasirikul","year":"2011","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijid.2022.04.052_bib0017","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ijantimicag.2016.04.025","article-title":"Pharmacokinetics and pharmacodynamics of meropenem in children with severe infection","volume":"48","author":"Kongthavonsakul","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijid.2022.04.052_bib0018","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1007\/s11908-010-0128-x","article-title":"Early antimicrobial therapy in severe sepsis and septic shock","volume":"12","author":"Kumar","year":"2010","journal-title":"Curr Infect Dis Rep"},{"key":"10.1016\/j.ijid.2022.04.052_bib0019","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1128\/AAC.00294-06","article-title":"Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections","volume":"51","author":"Li","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2022.04.052_bib0020","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s10096-019-03769-8","article-title":"Diagnostic and medical needs for therapeutic drug monitoring of antibiotics","volume":"39","author":"Mabilat","year":"2020","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijid.2022.04.052_bib0021","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s40265-018-0880-z","article-title":"Therapeutic drug monitoring of beta-lactams and other antibiotics in the intensive care unit: which agents, which patients and which infections?","volume":"78","author":"Muller","year":"2018","journal-title":"Drugs"},{"issue":"Suppl. 1","key":"10.1016\/j.ijid.2022.04.052_bib0022","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1086\/590064","article-title":"Pharmacokinetic and pharmacodynamic properties of meropenem","volume":"47","author":"Nicolau","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2022.04.052_bib0023","doi-asserted-by":"crossref","first-page":"523","DOI":"10.2133\/dmpk.DMPK-11-RG-027","article-title":"Optimal dosage regimen of meropenem for pediatric patients based on pharmacokinetic\/pharmacodynamic considerations","volume":"26","author":"Ohata","year":"2011","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1016\/j.ijid.2022.04.052_bib0024","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1002\/phar.2617","article-title":"Scoping review of augmented renal clearance in critically ill pediatric patients","volume":"41","author":"Rhoney","year":"2021","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijid.2022.04.052_bib0025","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1164\/rccm.201601-0024OC","article-title":"Continuous versus intermittent \u03b2-lactam infusion in severe sepsis. A meta-analysis of individual patient data from randomized trials","volume":"194","author":"Roberts","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ijid.2022.04.052_bib0026","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1097\/CCM.0b013e3181961bff","article-title":"Pharmacokinetic issues for antibiotics in the critically ill patient","volume":"37","author":"Roberts","year":"2009","journal-title":"Crit Care Med"},{"key":"10.1016\/j.ijid.2022.04.052_bib0027","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/cid\/ciu027","article-title":"DALI: defining antibiotic levels in intensive care unit patients: are current beta-lactam antibiotic doses sufficient for critically ill patients?","volume":"58","author":"Roberts","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2022.04.052_bib0028","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.ijantimicag.2010.06.008","article-title":"Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept","volume":"36","author":"Roberts","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijid.2022.04.052_bib0029","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1136\/ejhpharm-2018-001713","article-title":"Usefulness of therapeutic drug monitoring of piperacillin and meropenem in routine clinical practice: a prospective cohort study in critically ill patients","volume":"27","author":"Schoenenberger-Arnaiz","year":"2020","journal-title":"Eur J Hosp Pharm"},{"key":"10.1016\/j.ijid.2022.04.052_bib0030","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1681\/ASN.2008030287","article-title":"New equations to estimate GFR in children with CKD","volume":"20","author":"Schwartz","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ijid.2022.04.052_bib0031","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/INF.0000000000001445","article-title":"Abdel-Hady H. Conventional versus prolonged infusion of meropenem in neonates with Gram-negative late-onset sepsis: a randomized controlled trial","volume":"36","author":"Shabaan","year":"2017","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.ijid.2022.04.052_bib0032","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1093\/jac\/dkv123","article-title":"Can therapeutic drug monitoring optimize exposure to piperacillin in febrile neutropenic patients with haematological malignancies? A randomized controlled trial","volume":"70","author":"Sime","year":"2015","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl. 1","key":"10.1016\/j.ijid.2022.04.052_bib0033","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/1469-0691.12427","article-title":"ESCMID guidelines for the management of the infection control measures to reduce transmission of multidrug-resistant Gram-negative bacteria in hospitalized patients","volume":"20","author":"Tacconelli","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijid.2022.04.052_bib0034","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1093\/jac\/dkf130","article-title":"Pharmacodynamics of cefepime in patients with Gram-negative infections","volume":"50","author":"Tam","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2022.04.052_bib0035","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1007\/s00134-013-3088-4","article-title":"Clinical implications of antibiotic pharmacokinetic principles in the critically ill","volume":"39","author":"Udy","year":"2013","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.ijid.2022.04.052_bib0036","doi-asserted-by":"crossref","first-page":"5520","DOI":"10.1128\/AAC.00712-15","article-title":"Meropenem population pharmacokinetics in critically ill patients with septic shock and continuous renal replacement therapy: influence of residual diuresis on dose requirements","volume":"59","author":"Ulldemolins","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2022.04.052_bib0037","unstructured":"United States Food and Drug Administration. Merrem IV, 2016, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/050706s037lbl.pdf. (accessed 1 February 2022)."},{"key":"10.1016\/j.ijid.2022.04.052_bib0038","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/S1473-3099(17)30615-1","article-title":"Prolonged versus short-term intravenous infusion of antipseudomonal \u03b2-lactams for patients with sepsis: a systematic review and meta-analysis of randomised trials","volume":"18","author":"Vardakas","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijid.2022.04.052_bib0039","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ijid.2021.08.031","article-title":"Population pharmacokinetics of meropenem in critically ill infant patients","volume":"111","author":"Yonwises","year":"2021","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.ijid.2022.04.052_bib0040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0201667","article-title":"Clinical outcomes of prolonged infusion (extended infusion or continuous infusion) versus intermittent bolus of meropenem in severe infection: A meta-analysis","volume":"13","author":"Yu","year":"2018","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ijid.2022.04.052_bib0041","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.2165\/00003495-200767070-00006","article-title":"Comparative review of the carbapenems","volume":"67","author":"Zhanel","year":"2007","journal-title":"Drugs"},{"key":"10.1016\/j.ijid.2022.04.052_bib0042","first-page":"10","article-title":"Extended or continuous infusion of carbapenems in children with severe infections: a systematic review and narrative synthesis","author":"Zhou","year":"2021","journal-title":"Antibiotics (Basel)"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971222002533?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971222002533?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T08:07:39Z","timestamp":1761120459000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971222002533"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":42,"alternative-id":["S1201971222002533"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2022.04.052","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic drug monitoring of meropenem and pharmacokinetic-pharmacodynamic target assessment in critically ill pediatric patients from a prospective observational study","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2022.04.052","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}]}}